

## Prevention & Treatment of Hepatitis and Chronic Liver Disease

**Miami, FL April 27, 2024**

|  |   |   |
|--|---|---|
| <b>Conference Location</b>                       | <b>Sonesta Hotel-Miami International</b><br>950 NW Le Jeune Road<br>Miami, FL<br>(305)446-9000  | <a href="https://www.sonesta.com/sonesta-hotels-resorts/fl/miami/sonesta-miami-airport">https://www.sonesta.com/sonesta-hotels-resorts/fl/miami/sonesta-miami-airport</a> |
| <b>Parking and Guest Rooms at the Conference</b> | We have arranged for discounted Self-Parking for \$6. Please bring your ticket to our Registration Desk<br><br>A <b>special guest room rate of \$139</b> is available for Friday evening, April 26. Please book your room by <b>April 3</b>   |   |
| <b>Driving Directions</b>                        | <b>From Miami</b> take the Tamiami Trail (US 41) west. Turn right onto SW 42nd Ave/S Le Jeune Rd. The hotel will be on your left, just past NW 9 <sup>th</sup> Street   |   |
| <b>Seminar Agenda and Syllabus Information</b>   | Registration begins at <b>7:30 a.m.</b> in the Royal Ballroom, Salons I-II<br><br><b>The Hepatitis and Chronic Liver Disease seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet, or personal computer. Instructions to download the <i>App</i> will be provided. Wi-Fi will be available without charge. |   |
| <b>Pre-Program Activities</b>                    | <b>Pre-Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min<br><b>Pre-Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min   |   |
| <b>7:30 am</b>                                   | <b>Registration and View Exhibits</b>   |   |
| <b>8:00 am</b>                                   | <b>Opening Comments and Pre-Test</b>  |   |
| <b>8:20 am</b>                                   | <b>Advances in the Screening and Treatment of HCV</b> <ul style="list-style-type: none"> <li>• Updates on diagnostic approaches</li> <li>• Caring for At-risk populations – homeless, PWID, the incarcerated</li> <li>• Novel FDA Approved Direct Acting Anti-virals</li> <li>• Clinical Cases and Discussion</li> </ul>  |   |
| <b>9:10 am</b>                                   | <b>Hepatitis B: Epidemiology, History, Testing and Treatment</b> <ul style="list-style-type: none"> <li>• The epidemiology of the Hepatitis B infection</li> <li>• Efficacies and opportunities in HBV testing and vaccination</li> <li>• The efficacy of HBV Vaccination and Anti-viral therapies of HBV</li> <li>• HBV Re-activation and the Latest studies from EASL and AASLD</li> </ul>                              |   |
| <b>9:40 am</b>                                   | <b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>• Global and US perspective on the growth of Delta Hepatitis</li> <li>• Lonafarnib and Bulevirtide of HDV: Benefits and potential hazards</li> <li>• Testing and surveillance approaches</li> <li>• Real world outcome studies on HDV and HEV</li> </ul>   |   |
| <b>10:15 am</b>                                  | <b>Industry Presentation, Break and View exhibits</b>   |   |
| <b>11:00 am</b>                                  | <b>End Stage Liver Disease: Recap and Clinical Cases</b> <ul style="list-style-type: none"> <li>• A review of Pre-course lecture on end-stage liver disease</li> <li>• Complications of cirrhosis</li> <li>• Liver transplant in the era of DAA's<br/>Clinical cases to illustrate HE, HRS and/or Thrombocytopenia</li> </ul>   |   |
| <b>11:30 am</b>                                  | <b>Hepatocellular Carcinoma(HCC) - Screening and Disease Progression</b> <ul style="list-style-type: none"> <li>• Screening diagnostic serum assays and imaging tests</li> <li>• Treatment and management options: Ablation, TACE and Surgery</li> <li>• New studies showing cost effectiveness of surveillance post SVR</li> </ul>   |   |

|                         |   |
|-------------------------|---|
|                         | <ul style="list-style-type: none"> <li>• PRIUS Study (MRI vs US) Abbreviated MRI</li> <li>• 2023 AASLD screening guidance for liver cancer and comments on biopsy for HCC</li> </ul>  |
| 12:00 pm                | <b>Hepatocellular Carcinoma: A case-based approach to New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>• Promising 1<sup>st</sup> and 2<sup>nd</sup> line therapies for liver cancer</li> <li>• New data on the benefit of downstaging</li> <li>• C chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC</li> <li>• Checkpoint inhibitors and VEGE inhibitors</li> </ul>  |
| 12:35 pm                | <i>Luncheon and Product Information Session</i>   |
| 1:05 pm                 | <i>Dessert and View Exhibits</i>  |
| 1:20 pm                 | <b>Cholestatic Liver Disease: Primary Biliary Cholangitis and Primary Sclerosing Cholangitis</b> <ul style="list-style-type: none"> <li>• Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>• Causes and Markers of PBC</li> <li>• Coping with the clinical features of PBC</li> <li>• Ursodeoxycholic Acid (UDCA) and Obeticholic Acid</li> <li>• Highlights of the ELATIVE study on elafibanor and the RESPONSE study on seladelpar</li> </ul>  |
| 2:05 pm                 | <b>Alcohol Associated Liver Disease</b> <ul style="list-style-type: none"> <li>• The growing prevalence of alcohol over-consumption and its impact on liver health</li> <li>• Alcohol consumption and malnutrition</li> <li>• Warning signs and intervention in alcohol-associated hepatitis</li> <li>• Promising therapeutic agents for AAH</li> </ul>   |
| 2:35 pm                 | <i>Break &amp; View Exhibits</i>  |
| 2:50 pm                 | <b>Steatotic Liver Disease: The new healthcare epidemic</b> <ul style="list-style-type: none"> <li>• New naming conventions for fatty liver disease: MASLD and MASH– what and why?</li> <li>• Epidemiology, Demographics and Diagnosis</li> <li>• Scoring, Staging and Management of Metabolic Liver Disease</li> <li>• The ‘unhealthy’ rise in MASLD in the US population and What can be done</li> <li>• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.</li> </ul> |
| 3:25 pm                 | <b>MASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>• Current therapies for NASH including Updates from AASLD and EASL</li> <li>• Lifestyle changes as a therapy</li> <li>• Drugs in clinical development for NASH – Semaglutide and Resmitemon</li> <li>• MASH Diagnosis and Treatment case</li> </ul>  |
| 4:05 pm                 | <b>Closing Comments, Post-test and Wrap-Up</b><br>Program adjourns at 4:15 pm   |
| Post-program activities | <b>Lecture 3 - Fluid Management, Ascites and Hepatorenal Syndrome</b> 30 minutes<br><b>Lecture 4 - Overcoming barriers to liver health in special populations</b> - 30 minutes.<br><b>Lecture 5 – AASLD Update – Highlights of the 2023 Liver Meeting</b> – 30 minutes  |

#### Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

#### Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

#### Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

#### Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

#### Attendance Policies

---


**CME  
Information**

**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)<sup>TM</sup>**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1383. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)<sup>TM</sup> organizations accredited by ACCME.

---



**PAUL MARTIN, MD**

*Paul Martin is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, Miami, USA. He is a native of Dublin, Ireland, where he graduated with honors from medical school at University College, Dublin. He received a Doctorate in Medicine from the National University of Ireland.*

*Dr. Martin specializes in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Fellow in the Liver Unit at the National Institutes of Health in Maryland. He is Editor-in Chief of Liver Transplantation and Chair of the Gastroenterology Board at ABIM where he serves on the Council. He was previously a Councilor at Large on the Board of the American Society of Transplant. He is a Fellow of the Royal Colleges of Physicians of Ireland and London. He has had a long-standing interest in viral hepatitis and organ transplant.*



**BINU JOHN, MD, MPH**

*Binu John is an Associate Professor of Medicine at the University of Miami, and Associate Chief of Medicine, Chief of Gastroenterology and Hepatology, and Director of the CSP-NODES at the Miami VA Health System. He is also a practicing gastroenterologist and hepatologist with a broad background in clinical, outcomes and translational research, with specific training in epidemiology and clinical research.*

*Dr John's research is focused on hepatocellular carcinoma (HCC), viral hepatitis, and cirrhosis of the liver, and has expertise, leadership experience, clinical training, temperament, and strong motivation to carry out successfully this proposed work. He received his medical degree and completed his residency at Christian Medical College, Vellore, India and a Master of Public Health degree with emphasis on Epidemiology from the University of Minnesota. Dr. John completed two fellowships (Gastroenterology and Transplant Hepatology) at the Cleveland Clinic in Cleveland, Ohio.*

**Your Seminar  
Faculty**



**CARLA MOLLINER, MMS, PA-C**

*Carla Molliner is a nationally certified physician assistant specializing in hepatology at the University of Miami, Hepatology division. She graduated and completed PA school from Miami-Dade College in 2004 then earned her Master of Medical Science degree at Nova Southeastern University. She holds the national board recertification examination by the National Commission for Certification of Physician Assistants.*

*Carla was awarded an NP/PA clinical Hepatology fellowship from the American Association for the Study of Liver Disease (AASLD) between 2005 and 2006. Followed by joining the University of Miami in the outpatient Hepatology clinic. She then joined the inpatient hepatology consult team and has been an integral member for the past three years. She was recognized as a "U"-Shine employee for continuously exhibiting teamwork, professional manner, and excellent patient care among other distinguished behaviors*

---